Physician profile
Paul Row
NPI 1548345580
$5,462.19
in general payments reported to CMS, 2019-2025
29 companies · $878 in 2025
The $878 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $809 · 2020: $145 · 2021: $676 · 2022: $913 · 2023: $1,101 · 2024: $940 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,902 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,901.82 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,644.73 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Abbvie INC. | $1,049.32 | 2022-2025 | Durysta, Lumigan |
| Biotissue Holdings INC. | $367.89 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $248.91 | 2021-2023 | Acthar |
| Regeneron Healthcare Solutions, INC. | $234.50 | 2021-2025 | Eylea Hd, Eylea |
| Sight Sciences, INC. | $222.61 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Oyster Point Pharma, INC. | $197.89 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $191.72 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $169.70 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $132.03 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $124.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $109.79 | 2019 | |
| Thea Pharma INC. | $106.67 | 2023-2025 | Iyuzeh |
| Glaukos Corporation | $92.30 | 2020-2025 | Photrexa Viscous and Photrexa, Idosetr |
| Allergan, INC. | $87.89 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $64.09 | 2022-2023 | Alrex, Prolensa, Zylet |
| Kala Pharmaceuticals, INC. | $50.17 | 2020-2021 | |
| Rxsight INC | $49.97 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Sun Pharmaceutical Industries INC. | $48.05 | 2022-2023 | Cequa |
| Carl Zeiss Meditec, INC. | $44.34 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $35.40 | 2019-2020 | |
| Lkc Technologies, INC. | $33.00 | 2025 | |
| Ivantis, INC | $28.71 | 2019 | |
| Harrow Eye, LLC | $25.38 | 2024 | Vevye |
| Optos, INC. | $25.00 | 2021 | |
| Coopervision INC. | $22.26 | 2021 | |
| Genentech USA, INC. | $18.72 | 2023 | Vabysmo |
| Alcon Research LLC | $18.59 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $18.00 | 2023 | Tecnis Iol, Tecnis Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Row listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.